Effectiveness of a Multi-Modal Workplace Rest Cabin on Worker Well-Being (RECHARJME-RCT)

January 6, 2026 updated by: Simon Coulombe, Laval University

A Pragmatic Randomized Controlled Trial on the Effectiveness of a Multi-Modal Rest Cabin in Boosting Worker Well-Being

This study examines whether access to a rest cabin in the workplace supports employee well-being. Employees of a Canadian insurance company are randomly assigned to one of two groups: immediate access to the rest cabin or a waiting-list control group that receives access after one month. The rest cabin is installed directly in the workplace and can be reserved for short sessions during the workday. It offers multiple relaxation options, including guided meditation, massage therapy, light therapy, and a zero-gravity chair. Employees choose which options to use during each session. Participants complete questionnaires before group assignment and again one month later. Employees who receive immediate access to the cabin also complete additional follow-up questionnaires at later time points. The study compares changes in general well-being and work-related outcomes between employees who have access to the cabin and those who do not during the initial study period.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This pragmatic randomized controlled trial evaluates the effects of a multi-modal rest cabin on general and work-related well-being among employees of a Canadian insurance company. The study takes place in real-world workplace settings across multiple office locations. After providing informed consent, participants complete a baseline survey assessing general well-being and work-related outcomes. Participants are then randomly assigned to one of two conditions: (1) immediate access to the rest cabin or (2) a waiting-list control condition with delayed access. Employees assigned to the immediate-access group are encouraged to use the rest cabin over a four-week period. Cabin sessions are self-scheduled during work hours and are designed to be brief. The rest cabin is fully enclosed and located within the workplace. It includes several relaxation modalities, such as guided meditation, massage therapy, light therapy, and a zero-gravity chair. Participants are free to select and combine modalities based on their preferences during each session. Participants in both the immediate-access group and the waiting-list control group complete a follow-up survey one month after the baseline assessment. To examine whether any observed changes are maintained over time, participants in the immediate-access group also complete additional follow-up surveys two months and four months after baseline. It is hypothesized that workers in the experimental (vs. control) group would have better changes in scores in their general (positive and negative affect, flourishing, anxiety, depression, mindful attention awareness, insomnia) and workplace (thriving at work, burnout, absenteeism, presenteeism, job satisfaction, psychological detachment from work) positive and negative well-being when comparing Time 1 (follow-up survey) to Time 0 (baseline) (H1). Specific to those in the experimental condition, it is hypothesized that: positive changes observed following cabin use (at Time 1) would remain evident at the subsequent follow-up timepoints (Times 2 and 3), relative to baseline (H2), and changes in well-being outcomes between Time 1 and Time 0 would be greater for those who have used the cabin more often (H3). It is also hypothesized that: 4) the change in outcomes between T1 and T0 associated with being in the experimental (vs. control) condition (as discussed in H1) would be mediated by changes in psychological detachment from work and mindfulness awareness (H4), and 5) the relationship between cabin use frequency and changes in well-being outcomes (as discussed in H3) would be mediated by changes in psychological detachment and mindfulness awareness (also between T1 and T0; H5).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
82

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Mississauga, Ontario, Canada
        • Worksite 3
    • Quebec
      • Longueuil, Quebec, Canada
        • Worksite 3
      • Québec, Quebec, Canada
        • Worksite 1
      • Québec, Quebec, Canada
        • Worksite 2

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Employee of participating insurance company
  • Aged 18 or older

Exclusion Criteria:

  • Mental health leave in past year
  • Diagnosed mental health disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Rest Cabin Use
Participants are encouraged to use the Recharjme cabin for one month (four weeks) at a frequency of three times a week, preferably between 9 a.m. and 4 p.m.
Device: Recharjme Multi-Modal Rest Cabin
Enclosed workplace cabin with guided meditation, massage, luminotherapy, and zero-gravity chair.
No Intervention: Waiting List Control
No cabin access for four weeks.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Presenteeism (impaired productivity and troublesome symptoms at work)
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using the Employment Absence and Productivity Scale; Min.: 1; Max.: 5; Higher scores indicating a more negative outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Absenteeism
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Calculation based on the World Health Organization Health and Work Performance Questionnaire; Min.: 0; Max.: 100; Higher scores indicating a more negative outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Job satisfaction
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using an adapted item from Life in Transition Survey; Min.: 1; Max.: 5; Higher scores indicating a more positive outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Anxiety and depression
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using the two subscales of the Patient Health Questionnaire-4; Min.: 1; Max.: 4; Higher scores indicating a more negative outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Insomnia
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using the Insomnia Severity Index; Min.: 0; Max.: 4; Higher scores indicating a more negative outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Burnout (physical fatigue, cognitive weariness, emotional exhaustion)
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using the three subscales of the Shirom-Melamed Burnout Measure; Min.: 1; Max.: 7; Higher scores indicating a more negative outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Flourishing
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using the Flourishing Scale; Min.: 1; Max.: 7; Higher scores indicating a more positive outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Thriving at work
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using Index of Psychological Well-Being at Work (Thriving at Work Subscale); Min.: 0; Max.: 5; Higher scores indicating a more positive outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Mindful attention awareness
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using the Mindful Attention Awareness Scale (Carlson & Brown, 2005); Min.: 1; Max.: 6; Higher scores indicating a more positive outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Psychological detachment from work
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using adapted items from Recovery Experience Questionnaire; Min.: 1; Max.: 5; Higher scores indicating a more positive outcome.
Time 0 (baseline) to time 3 (four months after baseline)
Positive and Negative Affect
Time Frame: Time 0 (baseline) to time 3 (four months after baseline)
Measured using the two subscales of the Positive and Negative Affect Schedule; Min.: 1; Max.: 5; For positive affect: higher scores indicating a more positive outcome; For negative affect, higher scores indicating a more negative outcome.
Time 0 (baseline) to time 3 (four months after baseline)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Laval University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Mitacs

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Simon Coulombe, PhD, Laval University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 10, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 10, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 22, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 22, 2025

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 7, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 8, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Recharjme-RCT-2024
  • 2023-2766 (Other Identifier: Comité d'éthique de la santé des populations et première ligne (CIUSSS-CN))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings